CompletedNCT04372446
Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency
Studying Autosomal recessive hypophosphatemic rickets
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inozyme Pharma
- Principal Investigator
- Pedro Huertas, MDInozyme Pharma
- Enrollment
- 38 enrolled
- Eligibility
- All sexes
- Timeline
- 2020 – 2020
Study locations (1)
- Engage Health, Eagan, Minnesota, United States
Collaborators
GACI Global · Engage Health Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04372446 on ClinicalTrials.govOther trials for Autosomal recessive hypophosphatemic rickets
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07473973ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 DeficiencyInozyme Pharma
- ACTIVE NOT RECRUITINGPHASE3NCT06046820The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 DeficiencyInozyme Pharma
- RECRUITINGPHASE1NCT05734196The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 DeficiencyInozyme Pharma
See all trials for Autosomal recessive hypophosphatemic rickets →